Pharma Marketing Compliance: What AI Content Tools Get Wrong

AI can write faster, but it cannot navigate FDA regulations. Here is your compliance checklist for AI-assisted pharma content.

Full Analysis

"Summary: AI content tools can generate pharmaceutical marketing copy in seconds. They also get FDA compliance wrong in ways that can trigger warning letters, fines, and pulled campaigns. After reviewing AI-generated content for 8 pharma brands, here is a compliance checklist for teams using these tools.

The Speed Trap

A pharma marketing director told me something last year that stuck: ""We used to spend six weeks getting one email approved. Now we can generate 50 emails in an afternoon. The problem is, we still need six weeks to get each one approved.""

I remember that tension from my days at Intouch Solutions (now [Eversana Intouch](https://www.eversanaintouch.com/)). We would build a campaign, nail the creative, get everyone internally excited, and then watch it sit in MLR review for weeks. Sometimes months. A single landing page could take longer to approve than it took to design, develop, and QA the entire site. It was maddening. But that process existed for a reason, and AI does not change the reason. AI content tools solve a production problem. They do not solve a compliance problem. And in pharma, the compliance problem is the only one that matters.

I have reviewed AI-generated content for 8 pharmaceutical brands across oncology, cardiology, immunology, and rare disease categories. Every single one had compliance issues that would have triggered regulatory action if published. Not minor issues. The kind that result in [FDA warning letters](https://www.fda.gov/drugs/enforcement-activities-fda/warning-letters-and-notice-violation-letters-pharmaceutical-companies).

What AI Gets Wrong About Fair Balance

The [FDA requires fair balance](https://www.fda.gov/drugs/prescription-drug-advertising/prescription-drug-advertising-questions-and-answers) in pharmaceutical promotion. Every efficacy claim must be accompanied by risk information of comparable prominence. AI tools consistently fail this requirement in three specific ways:

Risk minimization through language softening. AI naturally generates positive, helpful content. That is how it is trained. Ask it to write about a drug's benefits and it will produce enthusiastic, compelling copy. Ask it to include side effects and it will add them, but with softened language. ""Some patients may experience mild nausea"" instead of ""Nausea occurred in 34% of patients in clinical trials, leading to discontinuation in 8% of cases.""

The FDA does not care about tone. They care about accuracy and prominence. If your efficacy claims use strong language and your risk information uses hedged language, that is a fair balance violation.

Omission of Black Box warnings. In my review, AI tools omitted or buried Black Box warnings in 6 out of 8 cases where the promoted drug carried one. When prompted to include them, the tools placed them at the bottom of the content or reformulated them in softer language. A Black Box warning is the FDA's most serious warning. It must appear prominently. AI tools treat it as just another piece of information to incorporate.

Invented efficacy data. This is the most dangerous failure. AI tools occasionally fabricate clinical trial results. Not intentionally. They generate statistically plausible numbers that do not correspond to any actual trial. I found fabricated efficacy percentages in 3 of 8 content reviews. One piece cited a ""Phase III trial showing 67% improvement in symptom scores"" for a drug whose actual Phase III results showed 41% improvement.

If you publish fabricated efficacy data, even accidentally, the consequences extend beyond a warning letter. That is potential fraud.

The ISI Problem

The Important Safety Information section in pharmaceutical marketing is not optional. It is not a suggestion. And it is not something you can paraphrase.

AI content tools treat ISI content like any other text. They summarize it. They rephrase it. They occasionally reorganize it in ways that change the meaning. None of this is acceptable.

ISI must be taken directly from the approved prescribing information. Word for word. The [FDA's Office of Prescription Drug Promotion](https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-prescription-drug-promotion-opdp) reviews promotional materials against the PI label. Any deviation, even well-intentioned simplification, can trigger action.

One marketing team I worked with used AI to ""make the ISI more readable."" The AI simplified ""Serious and sometimes fatal infections including tuberculosis"" to ""Infections including tuberculosis may occur."" Removing ""serious and sometimes fatal"" from a safety warning is not simplification. It is risk minimization. Their medical-legal review caught it. If they had not, OPDP certainly would have.

Where AI Content Tools Actually Help in Pharma

I am not arguing against using AI in pharma marketing. I am arguing against using it without guardrails. There are specific use cases where AI tools add value without creating compliance risk:

First-draft generation with mandatory review. AI can produce initial drafts of non-promotional content: disease awareness materials, patient education resources, HCP congress summaries. These still require medical-legal-regulatory (MLR) review, but starting with an AI draft reduces production time by 40-60%.

Content repurposing across channels. Once a piece of content has been approved, AI can help adapt it for different channels: email, social, web, print. The key constraint is that the AI must work within the boundaries of already-approved claims and language. It should rearrange, not rewrite.

Competitive intelligence summaries. AI excels at synthesizing large volumes of competitor communications, clinical trial results, and market data into digestible summaries. This is internal-use content that does not face the same regulatory scrutiny as promotional materials.

Medical information response drafts. AI can generate first drafts of responses to medical information requests, pulling from approved sources. These always require pharmacist or medical director review before sending, but the draft quality saves significant time.

The Compliance Checklist for AI-Generated Pharma Content

After working through these issues across multiple brands, I developed a checklist that marketing teams can use before any AI-generated content enters MLR review:

Claims verification (every single claim):

• Does every efficacy claim match the approved prescribing information exactly?
• Are clinical trial results cited with correct study names, phases, and endpoints?
• Are percentages and statistical measures accurate to the source data?
• Are no new claims introduced that are not in the approved promotional materials?

Fair balance check:

• Is risk information given equal or greater prominence compared to efficacy claims?
• Are Black Box warnings included verbatim and placed prominently?
• Does the language describing risks match the severity level in the PI?
• Are contraindications listed completely, not selectively?

ISI verification:

• Is the ISI taken verbatim from the current prescribing information?
• Has no simplification, summarization, or reorganization occurred?
• Is the ISI version current (PIs get updated and AI training data may reference older versions)?

Regulatory language check:

• Are no off-label claims implied or stated?
• Is the indication stated precisely as approved?
• Are no comparative claims made without head-to-head trial data?
• Is the content free of superlatives (""best,"" ""safest,"" ""most effective"") unless supported by substantial evidence?

Source verification:

• Every statistic traces back to a real, published source
• No AI-hallucinated citations or journal references
• Publication dates verified (AI sometimes cites retracted or superseded studies)
• Run claims through [Perplexity](https://www.perplexity.ai/) for cross-referencing. Healthcare teams have gravitated toward Perplexity because it cites sources inline, so you can trace a claim back to the actual study or label in seconds instead of manually Googling each data point

The MLR Process Needs to Adapt

Here is the uncomfortable truth: most MLR review processes were not designed for AI-generated content. They were designed for content produced by humans who understood pharmaceutical regulations. The assumption was that the writer had basic compliance knowledge.

AI has no compliance knowledge. It has pattern recognition. Those are different things.

MLR teams reviewing AI-generated content need to assume zero compliance awareness in the source material. That means:

• Every factual claim gets verified against primary sources, not just spot-checked
• Risk information is compared line-by-line against the current PI
• Claims are checked against the approved promotional platform, not just for medical accuracy

This is more work, not less. The time savings from AI-generated first drafts get partially consumed by more rigorous review. But the net result is still faster than the traditional process, as long as reviewers know what to look for.

Some organizations are building AI-specific review checklists into their MLR workflows. [Veeva Vault PromoMats](https://www.veeva.com/products/vault-promomats/) and similar systems are adding AI content flagging features. These tools help, but they do not replace human judgment on compliance questions.

The Training Gap

The biggest risk is not the AI tool itself. It is the marketing team using it without understanding what it gets wrong.

Junior marketers who have grown up with AI tools sometimes trust the output too much. They see well-written, professional-sounding content and assume it is compliant. In consumer marketing, that assumption is mostly safe. In pharma, it is dangerous.

Every team using AI for pharma content needs training on:

1. What fair balance actually means (not the general concept, the specific FDA requirements) 2. How to verify clinical data against source publications 3. Why ISI cannot be modified, period 4. The difference between approved and off-label claims 5. How to use AI outputs as starting points, not finished products

For more on how AI tools fit into broader marketing strategy, I wrote about the distinction between [AI agents and AI tools](/insights/marketing-team-ai-agents-not-tools) and why that difference matters for compliance workflows.

What Changes With the 2026 FDA Draft Guidance

The FDA released draft guidance in January 2026 specifically addressing AI-generated promotional materials. While still in the comment period, the direction is clear: companies will be held to the same standards regardless of whether content was written by humans or machines.

Two provisions stand out:

1. Companies must document which content was AI-generated and which review steps were applied 2. AI tools used for promotional content must be validated against pharmaceutical compliance requirements

This is not surprising. But it does mean that ""we did not know the AI made an error"" will not be an acceptable defense in enforcement actions. The regulatory expectation is that your review process catches AI errors. Full stop.

Key Takeaways

• AI content tools fabricated clinical trial data in 3 of 8 pharma brand reviews, inventing plausible but incorrect efficacy percentages
• Fair balance violations appeared in every AI-generated promotional piece reviewed, primarily through language softening of risk information
• ISI must be verbatim from prescribing information. AI rewrites of safety language are compliance violations regardless of intent
• Use AI for first drafts of non-promotional content and approved content repurposing, not for generating new promotional claims
• MLR review of AI content requires full claims verification, not spot-checking. Assume zero compliance knowledge in the source material
• FDA 2026 draft guidance will require documentation of AI-generated content and validation of AI tools for promotional use"